期刊
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
卷 54, 期 1, 页码 21-26出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jpba.2010.07.043
关键词
Rimonabant; Polymorph; Analogue; Counterfeit; NIDA-41020
Acomplia was ordered over the internet resulting in the delivery of counterfeit Acomplia and imitation products. The tablets were analyzed for the presence of rimonabant. Using LC-DAD-MSn the presence of effective quantities of rimonabant was confirmed in samples A-D. Samples A and D also contained traces of the rimonabant analogue NIDA-41020. Furthermore, NIR spectroscopy on the tablets indicated the presence of an unapproved rimonabant polymorph in samples C and D which was confirmed by Raman spectroscopy and X-ray diffraction (XRD). In sample E a low dose of sibutramine was found as well traces of N-desmethylsibutramine and bis-N-desmethylsibutramine. Rimonabant was withdrawn from the market because of serious adverse events and lack of efficacy. The availability of poor quality products with rimonabant, impurities and unapproved polymorphs is worrying. Suspect weight-loss medicines should be screened for the presence of novel analogues. (C) 2010 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据